Dr. Birgitta Agerberth, PhD
Karolinska Institute
Biography & Research Background
Birgitta Agerberth, PhD, is a key researcher at Karolinska Institutet (Sweden) who was instrumental in the original isolation and biochemical characterization of LL-37. Her research focuses on the peptide's conformation, antibacterial activity, and expression in different tissues and immune cells. She also investigated LL-37's role in diseases such as cystic fibrosis and its presence in biofluids. Key publications: 'FALL-39, a putative human peptide antibiotic' (1995), 'Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37' (1998), and 'The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations' (2000). Birgitta Agerberth is referenced as a key scientist in LL-37 research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Birgitta Agerberth, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Birgitta Agerberth, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.